1. Introduction {#sec1}
===============

Breast cancer is the second leading cause of cancer related deaths in women \[[@B1]\]. While several targeted chemotherapeutics have been developed, the use of these drugs is limited to those patients who exhibit the proper cellular profile, such as triple negative or HER2 positive \[[@B2]--[@B7]\]. In lieu of these targeted therapies, a more nonspecific treatment must be utilized. Cyclophosphamide and paclitaxel are two commonly used chemotherapeutics for breast cancer \[[@B8]\]. Cyclophosphamide is an alkylating agent from a class of nitrogen mustards that will damage DNA, thus preventing cancer cells from reproducing \[[@B9], [@B10]\]. Paclitaxel interferes with the cell cytoskeleton by altering microtubule rearrangement \[[@B11]\]. Paclitaxel was the first taxane used in clinical trials and found to be used with ovarian and breast cancers resistant to chemotherapy and has been used*in vivo* studies for inhibiting mammary cancer growth, delaying mammary adenocarcinomas, and decreasing tumor angiogenesis \[[@B12]\]. Usage of paclitaxel with radiation, in initial therapy, was shown to improve survival \[[@B13]\].

Overall, both of those toxins have produced good outcomes; however when these toxins are used they are injected intravenously and spread throughout the whole body, indiscriminately causing death to both cancerous and noncancerous cells \[[@B14]--[@B17]\]. Commonly reported side-effects include hair loss, bladder damage, joint pain, and anemia \[[@B18], [@B19]\]. Additionally, while these drugs have typically been used for nonspecific treatment of breast cancer, they may in fact show mixed efficacy depending on the genetic background of the tumors, with some tumors now showing paclitaxel resistance \[[@B20]--[@B22]\]. It is our long-term goal to identify compounds which might exhibit higher levels of cell death while having reduced specificity and develop a mechanism for a more localized delivery of these compounds to reduce systemic toxicity.

Therefore, we have decided to examine cantharidin, a natural toxin that can induce apoptosis. Cantharidin is terpenoid that is secreted by several species of beetles of the Meloidae family, primarily the blister beetles, cardinal beetles, and soldier beetles, along with the Spanish fly*Lytta vesicatoria* \[[@B23]\]. It has been used extensively in traditional Chinese medicine as a topical treatment for MCV infections and warts \[[@B24]\]. Recent studies have indicated that cantharidin may act via inhibition of protein phosphatases I and IIA, activation of p53, inhibition of CDK1, and production of reactive oxygen species \[[@B24]--[@B27]\]. However, as cantharidin is a potent inducer of apoptosis, its safety as an anticancer agent is questionable. Li et al. \[[@B28]\] reported cantharidin selectivity in inducing cell death in pancreatic cancer over normal pancreatic cell lines, and cantharidin has shown potential for use in the treatment of colon and liver cancers \[[@B29], [@B30]\]; it is also highly toxic to the gastrointestinal tract and kidneys which can result in mortality \[[@B31], [@B32]\].

Our long-term goal is to create a chemotherapeutic that could be utilized locally to kill cancerous cells while leaving the surrounding tissues and rapidly dividing cells such as hair follicles and red blood cells intact. As part of this goal, we seek to identify a compound that exhibits a more rapid and complete toxicity than the currently available choices. It is our hypothesis that one of the toxins we are studying will clearly be more toxic than the other two and thus will be an ideal choice for moving forward in the development of new chemotherapy treatments. To compare the cytotoxicity of these potential chemotherapies, and since different cell backgrounds may result in different responses to toxin exposure, we have used three cancer cell models: MCF-7 cells, MDA-MB-231 cells, and SK-BR-3 cells. We applied cantharidin, cyclophosphamide, or paclitaxel to these cells for up to 96 hours and assessed cell viability. The results of these studies are presented herein.

2. Materials and Methods {#sec2}
========================

2.1. Cell Culture {#sec2.1}
-----------------

Three mammary adenocarcinoma cell lines were utilized: SK-BR-3 cells, which overexpress the Her2 gene, MDA-MB-231 cells, which are estrogen-receptor negative, and MCF-7 cells, which express the estrogen receptor. SK-BR-3 and MDA-MB-231 cells were maintained in DMEM/F12 media (Life Technologies, Grand Island, NY) supplemented with antibiotics (50 IU/mL penicillin, 50 *µ*g/mL streptomycin, and 5 *µ*g/mL gentamycin sulfate) and 10% newborn calf serum (Life Technologies, Grand Island, NY). MCF-7 cells were maintained in Eagle\'s modified essential medium (HyClone, GE Healthcare Bio-Sciences, Pittsburgh, PA) containing antibiotics as above and 5% calf serum (PAA, GE Healthcare Bio-Science Corp., Piscataway, NJ). All cells were maintained at 37°C in a 5% CO~2~ humidified environment.

2.2. MTT Assay {#sec2.2}
--------------

When cells reached a minimum of 75% confluency, they were washed with HBSS, trypsinized, resuspended in media, and plated into one 96-well plate per original 75 cm^3^ flask. After twenty-four hours, a set of plated cells was treated in triplicate in the respective media containing either 1 to 100 *μ*M cantharidin, 0.1 to 10 *µ*M paclitaxel, or DMSO vehicle control, or 10 to 1000 *μ*M cyclophosphamide or H~2~O vehicle control. This treatment was repeated on fresh cells after 24, 48, and 72 hours.

After a maximum of 96 hours of treatment, an MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, Sigma, St. Louis, MO) based cell viability assay was performed in the manner of Sargent and Taylor \[[@B33]\]. Briefly, MTT was added to each well to a final concentration of 0.5 mM, and cells were incubated at 37°C in a 5% CO~2~ incubator. After 3 hours, the MTT solution was removed and cells were solubilized in 200 *μ*L of DMSO. The amount of stain was quantified using a microplate reader at 570 nM. The data recorded represented the amount of viable cells in a well and were normalized to the untreated control wells for each experiment. A minimum of four experimental replicates were performed. Univariate analysis of variance (ANOVA) was performed using SPSS (IBM SPSS Statistics 21, IBM Corp., Armonk, NY).

3. Results and Discussion {#sec3}
=========================

MDA-MB-231, SK-BR-3, and MCF-7 breast cancer cells were exposed to a single chemotherapeutic drug at a range of concentrations spanning the IC~50~ for up to 96 hours. Viable cells were stained with MTT dye, which was converted to formazan by mitochondria in live cells \[[@B33]\]. The amount of formazan was then quantified using a microplate reader. Results were compared to the appropriate control, either DMSO or H~2~O. Statistical analysis of the resulting data was performed using SPSS. Univariate ANOVA indicated cross-interactions between all multifactorial combinations of cell type, toxin, concentration, and time of exposure, and thus smaller interactions (toxin, concentration, and time of exposure plus multifactorial combinations) were examined within each cell type when appropriate.

Cyclophosphamide is commonly utilized for the treatment of several cancers and is most potent after conversion to its active form by the liver \[[@B34]\]. We selected a treatment range of 10 to 1000 *µ*M or a water vehicle control, as these levels overlap or exceed the reported IC~50~ range of 0.2--17 *µ*M \[[@B35], [@B36]\]. Cells that were treated with cyclophosphamide showed minimal cell death ([Figure 1](#fig1){ref-type="fig"}). No significant differences were observed with up to 1000 *µ*M cyclophosphamide in the MDA-MB-231 cells ([Figure 1(a)](#fig1){ref-type="fig"}). In contrast, at this highest concentration, both the SK-BR-3 and the MCF-7 cells showed a reduction in cell viability when compared to the water control. In the SK-BR-3 cells, only 30% death was observed consistently at the highest concentration ([Figure 1(b)](#fig1){ref-type="fig"}). A similar difference was only observed at the longest treatment in the MCF-7 cells ([Figure 1(c)](#fig1){ref-type="fig"}). Thus, the MCF-7 and MDA-MB-231 cells were more resistant to cyclophosphamide than the SK-BR-3 cells. This was somewhat expected with our direct application of the toxin, as cyclophosphamide is not as toxic without being metabolized by the liver \[[@B37]\]. Franke et al. \[[@B38]\] showed that apoptosis nearly doubled in MCF-7 cells treated with between 0.001 and 1 *µ*M compared to control-treated cells, yet little effect was observed in MDA-MB-231 cells. Even with much higher concentrations of cyclophosphamide, we failed to detect similar levels of cell death.

Paclitaxel (Taxol) is another chemotherapeutic which is widely used in breast cancer treatments \[[@B39]--[@B41]\]. Paclitaxel has shown mixed efficacy dependent upon cell type as well, with an IC~50~ range of 0.02--100 nM \[[@B42]--[@B45]\]. Thus, we felt that it was more appropriate to aim for the higher end of this range to ensure cell death in our three cell lines. However, even at this higher dosage, paclitaxel showed limited toxicity ([Figure 2](#fig2){ref-type="fig"}). No significant differences in viability were observed at the 24- or 48-hour time points in any of the three cell lines, regardless of concentration used. In MDA-MB-231 cells, we did observe minor reductions in viability at 72 and 96 hours, although this was seen around the middle concentration of 1 *µ*M ([Figure 2(a)](#fig2){ref-type="fig"}). In the SK-BR-3 cells, recovery was observed after a temporary decrease in viability at 72 hours ([Figure 2(b)](#fig2){ref-type="fig"}). In the MCF-7 cells, a significant effect of time was observed as the 96-hour treatment showed lower survival than the vehicle control for both of the lower concentrations. Recent work has indicated that some cell types may be resistant to paclitaxel due to downregulation of LZTS1 \[[@B45], [@B46]\]. With the minute toxicological response we detected, combined with the resistance to paclitaxel now being observed, paclitaxel does not appear to be a good selection for a local chemotherapeutic.

Cantharidin has been sought out previously as a potential chemotherapy drug, as it shows a high level of toxicity in a variety of cancerous cell lines \[[@B24], [@B26], [@B27], [@B47], [@B48]\]. However, limited direct comparisons to current chemotherapeutics have been made. Chang et al. \[[@B49]\] report an IC~50~ of 50 *µ*M for cantharidin in MCF-7 cells, thus we selected a range of 1 to 100 *µ*M for our study. Unlike paclitaxel and cyclophosphamide, our data show that cantharidin was able to significantly reduce viability in all three cell lines ([Figure 3](#fig3){ref-type="fig"}). At 1 *µ*M cantharidin, up to thirty percent cell death was observed in the MDA-MB-231 cells ([Figure 3(a)](#fig3){ref-type="fig"}), and there was more than fifty percent cell death after at least 72 hours of treatment in the higher concentrations. In the other two cell lines, statistically significant cell death compared to the vehicle control was not consistently observed until the 100 *µ*M concentration. However, this is significantly more cell death than was observed for the other two toxins in each of the cell lines examined; when concentration is not factored in, there is a statistically more death for all three cell lines for cantharidin than either cyclophosphamide or paclitaxel (*P* \< 0.001).

While cyclophosphamide and paclitaxel show limited toxicity at their reported IC~50~ levels, our data indicate that cantharidin can reduce viability significantly regardless of cell milieu. Thus, cantharidin holds potential as a better chemotherapeutic option for cancers with a variety of genetic backgrounds. As cantharidin is effective without being metabolized by the liver, it could be injected locally into the tumor rather than being dosed systematically. However, we must consider that even with localized dosage, there is still a systemic risk of toxicity. Conflicting reports of cantharidin toxicity to the gastrointestinal and renal systems make the choice to utilize cantharidin a difficult one. There are studies that indicate that, in both*in vitro* environment using pancreatic cells and several clinical trials, cantharidin is more toxic to cancerous cells than noncancerous \[[@B28], [@B50], [@B51]\]. However, historical evidence dictates that the kidney and liver have shown particular sensitivity to cantharidin, due to their physiological role in clearance \[[@B31], [@B32], [@B52]\]. To reduce the potential toxicity of cantharidin to noncancerous cells, our next goal is to collaborate with chemists at our institution to develop a drug delivery mechanism which will protect the normal tissue and allow for directed cell death only in the area of the tumor. Nanoparticles hold much promise as an encapsulating agent \[[@B53], [@B54]\]. Additionally, nanoparticles reduce the severity of many of the side effects of conventional chemotherapy \[[@B55], [@B56]\]. Thus, future studies will focus upon creating a nontoxic shell from liposomes and hollow gold nanoparticles that will encapsulate the cantharidin to reduce its toxicity should it come in contact with nontumor cells. Once synthesized, a release mechanism will be identified to ensure delivery of the toxin to only the tumor. Understanding the interaction of these nanoparticles with cancerous and noncancerous cells will allow improved diagnosis and treatment in cancer research, including the delivery of chemotherapy and targeting of tumors.

4. Conclusion {#sec4}
=============

In each of our cell types examined, MDA-MB-231, SK-BR-3, and MCF-7 cells, we observed a high decrease in cell viability after cantharidin was applied when comparing it to the untreated control, reaching more than 80% cell death for each of the cell types after 96 hours of treatment with 100 *µ*M cantharidin. This is substantially more death than was observed for either paclitaxel or cyclophosphamide, two commonly prescribed chemotherapy agents. Thus, we have identified a more potent toxin that may be utilized for local, rather than systemic, dosing.
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![Viability of breast cancer cells after exposure to 10 *µ*M, 100 *µ*M, or 1000 *µ*M cyclophosphamide. MDA-MB-231 (a), SK-BR-3 (b), or MCF-7 (C) cells were treated for up to 96 hours with either cyclophosphamide or a water control. Significant differences compared to the vehicle control (\**P* \< 0.05) are indicated.](IJBC2014-423059.001){#fig1}

![Viability of breast cancer cells after exposure to 0.1 *µ*M, 1 *µ*M, or 10 *µ*M paclitaxel. MDA-MB-231 (a), SK-BR-3 (b), or MCF-7 (c) cells were treated for up to 96 hours with either paclitaxel or DMSO vehicle control. Significant differences compared to the vehicle control (\**P* \< 0.05) are indicated.](IJBC2014-423059.002){#fig2}

![Viability of breast cancer cells after exposure to 1 *µ*M, 10 *µ*M, or 100 *µ*M cantharidin. MDA-MB-231 (a), SK-BR-3 (b), or MCF-7 (c) cells were treated for up to 96 hours with cantharidin or DMSO vehicle control. Significant differences compared to the vehicle control (\**P* \< 0.05) are indicated.](IJBC2014-423059.003){#fig3}
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